English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with  NPM1  mutation to 106 AML with  NPM1  mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype ( p  = .009 and  p  = .007, respectively) and was enriched in mutations of genes involved in histone modification, including  ASXL1  ( p  = .007 and  p  = .008, respectively). AML harbored a higher average number of gene mutations ( p  = .002) including more frequent  PTPN11  mutations ( p  &lt; .001) and mutations of DNA-methylating genes including  DNMT3A  and  IDH1  (both  p  &lt; .001). MS had significantly shorter overall survival (OS) than AML (median OS: 44.9 vs. 93.2 months, respectively,  p  = .037). MS with  NPM1  mutation has a unique genetic landscape, and poorer OS, compared to AML with  NPM1  mutation.

leukemia and lymphoma

Myeloid sarcoma with  NPM1  mutation may be clinically and genetically distinct from AML with  NPM1  mutation: a study from the Bone Marrow Pathology Group